Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 6/2014

01-06-2014 | Research Article

Association between CD95L polymorphism and cervical cancer risk: evidence from a meta-analysis

Authors: Jing Zhu, Lei Lu, Xiang Cheng, Rongkai Xie, Zhengqiong Chen, Youfei Li, Guilan Lin, Jianmei Liu, Ying Yang

Published in: Tumor Biology | Issue 6/2014

Login to get access

Abstract

Several studies have assessed the association of CD95L polymorphism with cervical cancer risk, but the data lack the power to provide compelling evidence. In this study, we aimed to clarify the association through a meta-analysis. A comprehensive search was conducted in PubMed, Embase, and Web of Science. The fixed-effects model was used to calculate odds ratio (OR) with 95 % confidence intervals (CIs). A total of five papers with six case–control studies were derived and finally included in this meta-analysis. The overall estimate did not reveal any significant association between CD95L −844C/T polymorphism and cervical cancer risk. Subgroup analysis in Asian population indicated nonsignificant nevertheless potentially increased risk in CC genotype carriers in comparison with the carriers of CT + TT genotypes (ORCC vs. CT + TT = 1.16, 95 % CI = 0.99–1.36, P for heterogeneity = 0.231). Based on current epidemiological studies, this meta-analysis suggests that CD95L polymorphism may not be a risk factor contributing to cervical cancer development.
Literature
1.
Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 1995;267(5203):1456–62.CrossRefPubMed
2.
3.
Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001;411(6835):342–8.CrossRefPubMed
4.
5.
6.
7.
Muschen M, Warskulat U, Beckmann MW. Defining CD95 as a tumor suppressor gene. J Mol Med (Berl). 2000;78(6):312–25.CrossRef
8.
Kim R et al. The role of CD95 ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via CD95-mediated apoptosis and potential targets for cancer therapy. Cancer. 2004;100(11):2281–91.CrossRefPubMed
9.
Gastman BR et al. CD95 ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res. 1999;59(20):5356–64.PubMed
10.
O’Connell J et al. The CD95 counterattack: CD95-mediated T cell killing by colon cancer cells expressing CD95 ligand. J Exp Med. 1996;184(3):1075–82.CrossRefPubMed
11.
Gratas C et al. Up-regulation of CD95 (APO-1/CD95) ligand and down-regulation of CD95 expression in human esophageal cancer. Cancer Res. 1998;58(10):2057–62.PubMed
12.
Koyama S, Koike N, Adachi S. CD95 receptor counterattack against tumor-infiltrating lymphocytes in vivo as a mechanism of immune escape in gastric carcinoma. J Cancer Res Clin Oncol. 2001;127(1):20–6.CrossRefPubMed
13.
von Bernstorff W et al. Pancreatic cancer cells can evade immune surveillance via nonfunctional CD95 (APO-1/CD95) receptors and aberrant expression of functional CD95 ligand. Surgery. 1999;125(1):73–84.CrossRef
14.
Viard-Leveugle I et al. Frequent loss of CD95 expression and function in human lung tumours with overexpression of CD95L in small cell lung carcinoma. J Pathol. 2003;201(2):268–77.CrossRefPubMed
15.
Ye Y et al. Genetic variants in cell cycle control pathway confer susceptibility to bladder cancer. Cancer. 2008;112(11):2467–74.CrossRefPubMed
16.
Wu J et al. A novel polymorphic CAAT/enhancer-binding protein beta element in the CD95L gene promoter alters CD95 ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J Immunol. 2003;170(1):132–8.CrossRefPubMed
17.
Zhang Z et al. The CD95 ligand promoter polymorphism, rs763110 (−844C > T), contributes to cancer susceptibility: evidence from 19 case–control studies. Eur J Hum Genet. 2009;17(10):1294–303.PubMedCentralCrossRefPubMed
18.
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.CrossRefPubMed
19.
Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719–48.PubMed
20.
21.
22.
Lai HC et al. Genetic polymorphisms of CD95 and CD95L (CD95/CD95L) genes in cervical carcinogenesis: an analysis of haplotype and gene-gene interaction. Gynecol Oncol. 2005;99(1):113–8.CrossRefPubMed
23.
Ivansson EL et al. Variants of chemokine receptor 2 and interleukin 4 receptor, but not interleukin 10 or CD95 ligand, increase risk of cervical cancer. Int J Cancer. 2007;121(11):2451–7.CrossRefPubMed
24.
Kang S et al. CD95–1377 G/A polymorphism and the risk of lymph node metastasis in cervical cancer. Cancer Genet Cytogenet. 2008;180(1):1–5.CrossRefPubMed
25.
Chatterjee K et al. CD95 and CD95L gene polymorphisms are not associated with cervical cancer but differ among Black and mixed-ancestry South Africans. BMC Res Notes. 2009;2:238.PubMedCentralCrossRefPubMed
26.
Li H et al. Association between CD95/CD95 L genes promoter polymorphisms and pathogenic risk of cervical cancer. Zhonghua Zhong Liu Za Zhi. 2009;31(1):38–41.PubMed
27.
Dockrell DH. Apoptotic cell death in the pathogenesis of infectious diseases. J Infect. 2001;42(4):227–34.CrossRefPubMed
28.
29.
Zhang J, Xu X, Liu Y. Activation-induced cell death in T cells and autoimmunity. Cell Mol Immunol. 2004;1(3):186–92.PubMed
30.
Bennett MW et al. The CD95 counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with CD95 ligand expression by human esophageal carcinoma. J Immunol. 1998;160(11):5669–75.PubMed
31.
Gutierrez LS et al. The CD95/CD95-ligand system: a mechanism for immune evasion in human breast carcinomas. Breast Cancer Res Treat. 1999;54(3):245–53.CrossRefPubMed
32.
33.
Yang M et al. Functional variants in cell death pathway genes and risk of pancreatic cancer. Clin Cancer Res. 2008;14(10):3230–6.CrossRefPubMed
Metadata
Title
Association between CD95L polymorphism and cervical cancer risk: evidence from a meta-analysis
Authors
Jing Zhu
Lei Lu
Xiang Cheng
Rongkai Xie
Zhengqiong Chen
Youfei Li
Guilan Lin
Jianmei Liu
Ying Yang
Publication date
01-06-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-1652-3

Other articles of this Issue 6/2014

Tumor Biology 6/2014 Go to the issue

Research Article

EMMPRIN co-expressed with matrix metalloproteinases predicts poor prognosis in patients with osteosarcoma

Research Article

p16 CDKN2A SNP rs11515 was not associated with head and neck carcinoma

Research Article

Matrix metalloproteinase-13 expression in the progression of colorectal adenoma to carcinoma

Research Article

The Wnt/β-catenin signaling pathway is involved in the antitumor effect of fulvestrant on rat prolactinoma MMQ cells

Review

The function of EMSY in cancer development

Research Article

Association of C722T polymorphism in XRCC3 gene with larynx cancer: a meta-analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits